Lifecore (LFCR) Furnishes Investor Presentation as Exhibit 99.1

Lifecore Biomedical intends to use a presentation in discussions with investors, analysts and others and has furnished that presentation as Exhibit 99.1 to this Current Report.

Rhea-AI Filing Summary

Lifecore Biomedical intends to use a presentation in discussions with investors, analysts and others and has furnished that presentation as Exhibit 99.1 to this Current Report. The company says the Presentation will be posted on its investor relations website and that the material furnished in this Item (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act nor incorporated by reference into future Securities Act filings unless expressly stated.

This disclosure is a Regulation FD furnishing of investor materials and confirms where the Presentation will be available; the report is signed by the company's Chief Financial Officer.

Insights

Financial Analyst

TL;DR: Routine Reg FD presentation furnishing; provides clarity on how Lifecore will share investor materials but is not material financial news.

The filing states Lifecore will use and furnish a presentation to certain investors and analysts and will post the same on its IR website, with Exhibit 99.1 attached. Because the company specifies the furnishing is not "filed" under Section 18, the disclosure is administrative and intended to satisfy Regulation FD transparency requirements rather than to announce results or a material transaction. For investors, this signals organized investor communications but does not itself change financial metrics or obligations disclosed elsewhere.

Corporate Governance Expert

TL;DR: Governance disclosure confirms controlled distribution of investor materials and clarifies legal incorporation limits of the Presentation.

The Item explicitly furnishes the Presentation as Exhibit 99.1 and states it will be posted on the company website. Importantly, the company clarifies that the furnished information is not "filed" for Section 18 purposes and will not be incorporated by reference into Securities Act filings unless specifically referenced. That distinction limits legal incorporation risk for the company while maintaining transparency under Regulation FD, reflecting a standard governance approach to investor communications.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lifecore (LFCR) report in this 8-K?

The company reported it intends to use a presentation in discussions with investors and analysts and furnished that Presentation as Exhibit 99.1.

Is the Lifecore presentation publicly available and where?

Yes. The company stated the Presentation will be posted on its investor relations website at https://ir.lifecore.com/events-presentations.

Was the Presentation filed or just furnished?

The company indicated the Presentation and related information are furnished and expressly stated they shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Which exhibit contains the Lifecore presentation?

The Presentation is provided as Exhibit 99.1 to the Current Report.

Who signed the 8-K for Lifecore (LFCR)?

The report was signed on behalf of Lifecore Biomedical by Ryan D. Lake, Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2025 - 07:53 AM Learn about SEC filing dates

FALSE000100528600010052862025-08-122025-08-12

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

LIFECORE BIOMEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-27446

94-3025618

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)

3515 Lyman Boulevard
Chaska,			Minnesota			55318
(Address of principal executive offices)						(Zip Code)

(952) 368-4300

(Registrant’s telephone number, including area code)

 Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common stock, par value $0.001 per share

LFCR

The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01    Regulation FD.

Beginning on August 12, 2025, Lifecore Biomedical, Inc. (the “Company”) intends to use a presentation (the “Presentation”) in discussions with certain of its investors, analysts and others. A copy of the Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 7.01. A copy of the presentation will be furnished at, and posted on, the Company’s website (https://ir.lifecore.com/events-presentations).

The information furnished in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Lifecore Biomedical Presentation dated August 12, 2025

104

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 12, 2025

			LIFECORE BIOMEDICAL, INC.
By:			/s/ Ryan D. Lake
			Ryan D. Lake
			Chief Financial Officer